**Excerpt:** President Trump has signed an executive order to enhance research on psychedelics, including ibogaine, aimed at improving mental health treatment options.
Key Points
– President Trump signed an executive order to promote research on psychedelics, including ibogaine.
– The move is intended to address mental health issues, particularly for veterans suffering from PTSD.
– The federal government will invest $50 million in psychedelic research.
– Ibogaine, a Schedule I substance, is being considered for human trials to treat various conditions.
– Concerns remain about ibogaine’s safety, particularly regarding heart-related risks.
Full Article
Executive Order Overview
President Trump has signed an executive order aimed at easing research restrictions on psychedelics, including ibogaine, which is used in some countries to treat post-traumatic stress disorder (PTSD). The signing took place in the Oval Office, attended by Health and Human Services Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan.
Research Investment
Mr. Trump emphasized that the order would “dramatically accelerate access to new medical research and treatments based on psychedelic drugs,” which he described as having “life-changing potential.” He announced a federal investment of $50 million to support psychedelic research initiatives. Additionally, the government is creating a pathway for ibogaine to be administered to “desperately ill patients” under the FDA’s Right To Try rule.
Focus on Veterans
Highlighting the issue of veteran suicide rates, Trump stated, “Everybody is so strongly in favor of this. It’s for a lot of people, but it’s for our veterans in particular.” If successful, he believes these treatments could significantly impact the U.S. and other countries.
FDA’s Role
FDA Commissioner Marty Makary announced that three psychedelics would be added to the National Priority Voucher pilot program, facilitating quicker reviews of drugs aligned with U.S. health priorities. The FDA will also initiate the process for researchers to conduct human trials on ibogaine.
Safety Concerns
Ibogaine, a naturally occurring compound from an African shrub, has been linked to treating addiction, depression, and anxiety. However, its classification as a Schedule I substance by the Drug Enforcement Administration raises concerns. While it shows potential, particularly for opioid dependence, the current evidence is limited to small studies. Notably, ibogaine has been associated with dangerous heart rhythm disturbances, with at least 27 reported deaths following its use.
Conclusion
The executive order reflects a growing interest in exploring alternative treatments for mental health issues, while balancing the need for thorough research and safety evaluations. Further discussions are expected on how the federal government will facilitate this research moving forward.
Leave a Reply